Expression of bcl‐2 protein and Ki‐67 nuclear proliferation antigen in benign and malignant cutaneous T‐cell infiltrates
- 1 February 1995
- journal article
- Published by Wiley in Journal of Cutaneous Pathology
- Vol. 22 (1) , 11-17
- https://doi.org/10.1111/j.1600-0560.1995.tb00733.x
Abstract
The bcl-2 protein prolongs cell life by inhibiting apoptosis. Its expression has been studied in a variety of normal tissues and lymphomas but there is minimal information available concerning bcl-2 expression by benign and malignant cutaneous T-cells. Therefore, we investigated bcl-2 expression in a wide variety of cutaneous T-cell infiltrates using one- and two-color immunohistologic techniques, bcl-2 was expressed by the majority of lesional CD3+ T-cells in most cases. This included 22Departments of 26 cases of mycosis fungoides (MF), 3/3 cases of non-MF cutaneous T-cell lymphoma, 5/5 cases of lymphomatoid papulosis, 4/4 cases of T-cell rich cutaneous lymphoid hyperplasia, 2/3 cases of bullous pemphigoid, 2/2 cases of discoid lupus erythematosus and 1/1 case of lichen planus. Titration experiments and comparative studies of tonsil section positive controls revealed that, relative to mantle zone B-cells, there was over- expression of bcl-2 by a variable subset of T-cells in most cases. Assessment of multiple biopsies in a subset of MF cases showed stable expression of bcl-2 over intervals of up to two years. In contrast to the widespread expression of bcl-2 in both early and advanced MF skin lesions, abundant expression of the nuclear proliferation antigen, Ki-67, was skewed toward advanced MF skin lesions. Ten percnt or more Ki-67+ cells were present in 5% of patients with patches/thin plaques, 38% with moderate plaques, 64% with thick plaques and 100% with tumor nodules. Two-color immunohistologic analysis combined with molecular biologic analysis of clonality in the cases of T-cell rich cutaneous lymphoid hyperplasia indicated that bcl-2 expression was both a polyclonal and multi-lineage phenomenon, suggesting that it occurred by a physiologic rather than mutational mechanism. We conclude that bcl-2 expression is a common feature of cutaneous T-cell infiltrates that has minimal differential diagnostic value for distinguishing lymphomas from reactive T-cell infiltrates. In early MF lesions, abundant expression of bcl-2 and sparse expression of Ki-67 suggested that the accumulation of tumor cells during the initial progression of MF may be facilitated by prolonged clonal survival in conjunction with low-grade clonal proliferation.Keywords
This publication has 23 references indexed in Scilit:
- bcl-2 Protein Expression and Correlation with the Interchromosomal 14;18 Translocation in Cutaneous Lymphomas and PseudolymphomasJournal of Investigative Dermatology, 1994
- Mycosis fungoides: clinical and histologic features, staging, evaluation, and approach to treatmentCA: A Cancer Journal for Clinicians, 1993
- Bcl-2: a repressor of lymphocyte deathImmunology Today, 1992
- Interleukin 4 protects chronic lymphocytic leukemic B cells from death by apoptosis and upregulates Bcl-2 expression.The Journal of Experimental Medicine, 1992
- Interleukin-7 is a growth factor for Sézary lymphoma cells.Journal of Clinical Investigation, 1992
- Cytogenetic and molecular studies of t(14;18) and t(14;19) in nodal and extranodal B‐cell lymphomaThe Journal of Pathology, 1992
- bcl-2 transgene inhibits T cell death and perturbs thymic self-censorshipCell, 1991
- UPDATED KIEL CLASSIFICATION FOR LYMPHOMASThe Lancet, 1988
- An assessment of the diagnostic value of the monoclonal antibodies Leu 8, OKT9, OKT10 and Ki67 in cutaneous lymphocytic infiltratesBritish Journal of Dermatology, 1986
- Expression of a Cell-Cycle-Associated Nuclear Antigen (Ki-67) in Cutaneous Lymphoid InfiltratesThe American Journal of Dermatopathology, 1986